huPBMC-NCG

Wild Mouse 750
Wild Mouse 750
Human Xenograft Models
Cell Derived Xenograft Models
Autoimmune Disease Models
Myasthenia Gravis (MG) ModelsAutoimmune Nephropathy modelsAcute Lung Injury ModelsIdiopathic Pulmonary Fibrosis ModelsSjögren’ s Syndrome ModelsSystemic Lupus Erythematosus (SLE) ModelsMultiple Sclerosis ModelsRheumatoid Arthritis ModelsPsoriasis ModelsInflammatory Bowel Disease ModelsAtopic Dermatitis Models Asthma Models
Metabolic Disease Mouse Models
Obesity ModelsDiabetes ModelsMASH ModelsHyperlipidemia ModelsOsteoporosis ModelsHyperuricemia Models
Humanized Immune System Models
huPBMC-NCGhuHSC-NCG-XhuHSC-NCG-hIL15huHSC-NCG
Organs or Tissue Humanized Mouse Models
Wild Mouse 765
Wild Mouse 765
Rare Disease Mouse Models
Autosomal Dominant Polycystic Kidney Disease (ADPKD)Progressive Muscular Dystrophy ModelsHemophilia A Models
Neurological Disease Mouse Models
Alzheimer's Disease (AD) ModelsHumanized Alzheimer's Disease (AD) ModelsParkinson's Disease (PD) ModelsHuntington's Disease (HD) ModelsAmyotrophic Lateral Sclerosis (ALS) ModelsTransthyretin Amyloidosis (ATTR) ModelsPain Mouse ModelsDuchenne Muscular Dystrophy (DMD) Models
Oncology Mouse Models
Drug ResistanceT-Cell EngagersHuman Xenograft ModelsHumanized Immune Checkpoint ModelsHumanized Immune System ModelsSpontaneous Tumor Models

The huPBMC-NCG mouse model is generated by transplanting Peripheral Blood Mononuclear cells (PBMC) from healthy people into severe immunodeficient NCG mice to construct the human immune system reconstituted mouse model. This model shows fast reconstitution of immune cells, the majority of which are T cells. This system can be used to evaluate the preclinical efficacy of anti-tumor agents. The survival period of huPBMC-NCG mice is 5-7 weeks. Since the reconstitution of T cells is very fast, human T cells recognize and attack mouse tissues causing graft-versus-host disease (GvHD), which also makes this model appropriate for evaluating anti-GvHD drug efficacy. In order to exclude the influence of PBMC from different donor sources on the experimental outcomes, GemPharmatech has established  an huPBMC donor library through screening to ensure the stability of huPBMC-NCG immune reconstitution.

 

Strategy

图片1.png

hPBMCs were injected through the caudal vein (1x107cells) into NCG mice for huPBMC reconstitution.


Applications

  • Preclinical anti-tumor efficacy studies and safety evaluation

  • Short-term efficacy evaluation

  • Evaluation of anti-GvHD drugs


Supporting data

1. The survival curve of huPBMC-NCG

图片2.png

huPBMC from donors F and G were injected into NCG mice, and the survival time was analyzed. Since the implanted PBMC were heterologous immune cells, the huPBMC-NCG mice developed graft-versus-host disease (GvHD), in which the human-derived immune system attacked the mice's tissues and organs, ultimately resulting in death and shortening the application of the huPBMC-NCG mice. In this study, we discovered that mice transplanted with human PBMC died progressively after approximately one month.


2. The human immune reconstitution levels of the huPBMC-NCG mice

图片3.png

Human immune cell levels in peripheral blood of huPBMC-NCG mice were detected by flow cytometry. The levels of human leukocytes and T cells climbed progressively, and by the third week, the mean ratio of human leukocyte had surpassed 50%. Data are shown as Mean±SEM.

图片4.png

Using flow cytometry, the relative amounts of human leukocytes in the spleen, peripheral blood, and bone marrow of huPBMC-NCG mice were measured. Data are shown as Mean±SEM. *P<0.05; **P<0.01; ***P<0.001.


Get a Quote